OUR BLOGS
Check out our latest and upcoming Blogs.
Contact UsRSS September 22 2021 Daclatasvir is an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Daclatasvir use with Sofosbuvir with or without Ribavirin to treat HCV genotype 1 and 3 infections. Daclatasvir was FDA-approved in July 2015. September 17 2021 FCE pharma is highly acclaimed and much anticipanted event for pharmaceutical industry in Latin America. SynZeal will be presenting at FCE Pharma 21 at Booth No G-083 during this event scheduled on September 8 2021 Dabigatran is a direct inhibitor of thrombin and anticoagulant which is used for prevention of stroke and venous embolism in patients with chronic atrial fibrillation. Dabigatran was approved for medical use in 2010.
Daclatasvir
SynZeal is exhibiting in FCE Pharma 2021 in Sao Paulo, Brazil !
.png)
Dabigatran